Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the week of 11th May - 18th May Fosun Pharma ( Collaboration ) Fosun Pharma and AriBio sign an exclusive global agreement for the development, registration, manufacturing and commercialization of AR1001, a phosphodiesterase-5 inhibitor with disease-modifying potential to treat AD Alkermes ( Phase 3, Results ) Phase 3 REVITALYZ study of Alkermes evaluating LUMRYZ extended-release oral suspension in adults with idiopathic hypersomnia demonstrates significant improvements in excessive daytime sleepiness compared to placebo AstraZeneca ( Phase 3, Results ) AstraZeneca's VOLGA Phase 3 trial evaluating IMFINZI in combination with neoadjuvant enfortumab vedotin demonstrates clinically meaningful improvements in EFS and OS in muscle-invasive bladder cancer AstraZeneca ( Phase 3, Results ) The CALYPSO Phase 3 trial from AstraZeneca assessing AZP-3601 demonstrates clinically meaningful normalization of sCa levels and independence from active vitamin D and oral calcium supplements in adults with chronic HypoPT at week 24 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 11th May – 18th May in the world of pharma and healthcare!

May 18, 2026

Highlights from the week of 4th May - 11th May Lannett ( FDA, Approval ) FDA approves Lanex Biologics’ subsidiary Lannett and Sunshine Lake Pharma's interchangeable biosimilar, LANGLARA, to treat adult and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus Bristol Myers Squibb ( EU, Approval ) EC grants approval to Bristol Myers Squibb's SOTYKTU, a once-daily, oral, selective TYK2 inhibitor to treat active PsA in adults with inadequate or intolerant response to DMARD therapy Biocon ( Health Canada, Approval ) Biocon gets Health Canada approval for its micafungin injection, USP, 50 mg and 100 mg for the treatment and as a prophylaxis of various Candida infections in patients undergoing hematopoietic stem cell transplantation Merck ( Acquisition ) Merck acquires Terns Pharmaceuticals along with its Breakthrough Therapy Designation drug TERN-701, a potential treatment option for certain patients with chronic myeloid leukemia All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 04th May – 11th May in the world of pharma and healthcare!

May 11, 2026

Highlights from the Week of 27th April 2026 - 4th May 2026 ( FDA, Approval ) AstraZeneca's fixed-dose triple-combination therapy, BREZTRI AEROSPHERE, gains FDA approval for the maintenance treatment of asthma in patients aged 12 and older ( FDA, Approval ) Arvinas' VEPPANU receives FDA approval as the first-ever PROTAC therapy for the treatment of adults with ER+ or HER2- or ESR1 mutated, advanced or metastatic breast cancer ( FDA, Approval ) FDA approves Incyte's JAKAFI XR extended-release tablets to treat adults with intermediate- or high-risk myelofibrosis, polycythemia vera and adults or children who are 12 years and older with GVHD ( FDA, Approval ) Axsome secures approval from the FDA for its AUVELITY, targeting NMDA and sigma-1 receptors to treat dementia due to Alzheimer's disease Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 27th April 2026 – 4th May 2026 in the world of pharma and healthcare!

May 5, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

Q2 2026 earnings conference Call Aug 03,2026 To Aug 06,2026 Aug 03 Aug 04 Aug 05 Aug 06 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of August 03,2026 To August 06,2026

August 3, 2026

Q2 2026 Earnings Conference Call Jul 27,2026 To Jul 31,2026 Jul 29 Jul 28 Jul 27 JUl 30 Jul 31 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of July 27,2026 To July 31,2026

July 27, 2026

2026 RBC Capital Markets Global Healthcare Conference Q2 2026 Earnings Call July 21,2026 To July 23,2026 July 23 July 21 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of July 21,2026 To July 23,2026

July 20, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

INFLAMMATORY BOWEL DISE SE IBD is an umbrella term for a group of conditions that cause swelling and inflammation of the tissues in the digestive tract Global Prevalence and Incidence Country-wise affected population Prevalence 2.4-3.1M 229.7 per 100,000 2.5-3 M Incidence Low Low with increase 0.18 M High TYPES OF IBD Crohn's disease Ulcerative colitis Crohn's disease (CD): It can affect any part of the digestive tract from mouth to anus and causes deep, tissue-layer inflammation Ulcerative colitis (UC): It affects only the colon and rectum's inner lining, causing inflammation and ulcers DIAGNOSIS Blood Test Stool Test Upper Endoscopy Colonoscopy Tissue Biopsy Imaging Studies Risk factors Causes of inflammatory Bowel Disease Medium Women face a higher risk of CD; men face a higher risk of UC Smoking affects development and severity of Crohn's Commonly diagnosed between ages 15-35 Luminal Factors Microbiome Intestinal Immune System Alterations Environmental Factor Genetic Predisposition SYMPTOMS Loss of appetite Fatigue Stomach aches and cramps Weight loss Diarrhea Blood in your stool TREATMENT Surgery Bowel resection Top-down approach Nutritional support Probiotics Biologic therapy Adalimumab & Infliximab Immunosuppressants Methotrexate, Azathioprine & Mercaptopurine Corticosteroids Budesonide, Methylprednisolone & Prednisolone 5-ASA | Antibiotics 5 ASA- Mesalamine & Sulfasalazine | Antibiotics- Ciprofloxacin & Metronidazole Step-up approach Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

True workplace inclusivity means supporting employees with chronic, often invisible conditions. Inflammatory Bowel Disease (IBD) affects millions of professionals worldwide, impacting daily life, energy and productivity.This World IBD Day, let’s advocate for understanding, flexible workplaces, and healthcare support. 💼💜

May 19, 2026

High blood pressure isn’t just a clinical issue; it’s a productivity and workplace wellness issue. Given that stress is a major contributor to hypertension, the 2026 theme “Controlling Hypertension Together” hits home for leadership teams everywhere. Let’s foster environments where health is as important as the bottom line. 📈❤️

May 17, 2026

On World Lupus Day, we stand in support of everyone affected by lupus — raising awareness, encouraging early diagnosis, and advocating for better care and research. 💜Together, we can help improve lives through awareness, innovation, and compassion.

May 10, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message